Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 - 2022

Published: Sep, 2018 | Pages: 115 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, as per a new report by Grand View Research, Inc., experiencing a CAGR of 9.4% during the forecast period. Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

Further key findings from the report suggest:

• Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing to its higher usage by healthcare practitioners and easy availability

• TNF-inhibitors are likely to lose market shares over the forecast period due to increasing preference for IL-inhibitor therapy to conventional TNF-inhibitors

• Interleukin-inhibitors is expected to register a lucrative CAGR of over 21.0% during the forecast period owing to improved safety and efficacy profiles of Interleukin-inhibiting drugs

• The U.S is the dominant region in the psoriasis market in terms of revenue in 2016 due to increasing number of patients seeking treatment and presence of well-established healthcare services

• Japan is expected to be the fastest growing region during the same period due to growing awareness about the disease among the populace

• Some of the key players in this industry are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck.

 Table of Contents

Chapter 1 Research Methodology
                  1.1 Information Procurement
                  1.2 Information or Data Analysis
                      1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology
                  3.1 Disease Primer
                      3.1.1 Types:
                          3.1.1.1 Plaque Psoriasis
                          3.1.1.2 Guttate Psoriasis
                          3.1.1.3 Inverse Psoriasis
                          3.1.1.4 Pustular Psoriasis
                          3.1.1.5 Erythrodermic Psoriasis
                      3.1.2 Complications
                  3.2 Epidemiology by Indications
                  3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
                  3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
                  3.5 Forecast Prevalence and Incidence (U.S., Japan, EU5)

Chapter 4 Global Psoriasis Drugs Market Overview
                  4.1 Introduction and Market Overview
                      4.1.1 Market by Therapeutic Class
                          4.1.1.1 Tumour Necrosis Factor Inhibitors
                              4.1.1.1.1 Adalimumab
                              4.1.1.1.2 Infliximab
                              4.1.1.1.3 Etanercept
                          4.1.1.2 InterleU.K.in-Inhibitors
                              4.1.1.2.1 Ustekinumab
                              4.1.1.2.2 SecU.K.inumab
                              4.1.1.2.3 Ixekizumab
                              4.1.1.2.4 Brodalumab
                          4.1.1.3 Vitamin D analogues
                              4.1.1.3.1 Calcitriol
                              4.1.1.3.2 Calcipotriol
                              4.1.1.3.3 Tacalcitol
                      4.1.2 Market by Treatment
                          4.1.2.1 Topicals
                              4.1.2.1.1 Over-the-counter (OTC) Topicals
                              4.1.2.1.2 Topical non-steroids
                              4.1.2.1.3 Topical Steroids
                          4.1.2.2 Systemic
                              4.1.2.2.1 Retinoid
                              4.1.2.2.2 Cyclosporine
                              4.1.2.2.3 Methotrexate
                          4.1.2.3 Biologics
                              4.1.2.3.1 Tumour necrosis factor alpha (TNF-α) inhibitors
                              4.1.2.3.2 InterleU.K.in 12 and 23 (IL-12/23) inhibitors
                              4.1.2.3.3 InterleU.K.in 17 (IL-17) inhibitor
                              4.1.2.3.4 T cell inhibitor
                      4.1.3 Market Size & Forecast
                      4.1.4 Sales Performance
                      4.1.5 Market Share Distribution
                      4.1.6 Market Dynamics among Leading Brands
                  4.2 Patent Expiry Schedule
                  4.3 Drivers and Challenges
                  4.4 Deals Landscape (2013-2017)
                  4.5 Pricing and Reimbursement Environment
                  4.6 Biosimilar Evolution
                      4.6.1 India
                      4.6.2 China
                      4.6.3 South Korea
                  4.7 SWOT Analysis

Chapter 5 Global Psoriasis Drugs Market: Pipeline Intelligence
                  5.1 Pipeline Landscape
                      5.1.1 Leading Drugs under Development
                      5.1.2 Key R&D Trends
                  5.2 Promising Drug Candidates in Pipeline
                      5.2.1 Late Stage Pipeline and Forecast
                      5.2.2 Profile of Disruptive Drugs
                          5.2.2.1 Risankizumab
                          5.2.2.2 Bimekizumab

Chapter 6 Company Profiles
                  6.1 AbbVie Inc.
                      6.1.1 Company Overview
                      6.1.2 Current Product Portfolio
                      6.1.3 Product Forecast Sales up to 2022
                      6.1.4 Strategic Initiatives(Humira)
                      6.1.5 Company - Key News Flow
                      6.1.6 Pipeline View
                      6.1.7 Pipeline Forecast
                      6.1.8 Catalysts and Event Calendar
                      6.1.9 SWOT Analysis
                  6.2 Amgen, Inc.
                      6.2.1 Company Overview
                      6.2.2 Current Product Portfolio
                      6.2.3 Product Forecast Sales up to 2022
                      6.2.4 Strategic Initiatives(Enbrel)
                      6.2.5 Company - Key News Flow
                      6.2.6 Pipeline View
                      6.2.7 Pipeline Forecast
                      6.2.8 Catalysts and Event Calendar
                      6.2.9 SWOT Analysis
                  6.3 Johnson & Johnson
                      6.3.1 Company Overview
                      6.3.2 Current Product Portfolio
                      6.3.3 Product Forecast Sales up to 2022
                      6.3.4 Strategic Initiatives
                          6.3.4.1 Remicade
                          6.3.4.2 Stelara
                          6.3.4.3 Tremfya
                      6.3.5 Company - Key News Flow
                      6.3.6 Pipeline Forecast
                      6.3.7 Catalysts and Event Calendar
                      6.3.8 SWOT Analysis
                  6.4 Novartis AG
                      6.4.1 Company Overview
                      6.4.2 Current Product Portfolio
                      6.4.3 Product Forecast Sales up to 2022
                      6.4.4 Strategic Initiatives(Cosentyx)
                      6.4.5 Company - Key News Flow
                      6.4.6 Pipeline View
                      6.4.7 Pipeline Forecast
                      6.4.8 Catalysts and Event Calendar
                      6.4.9 SWOT Analysis
                  6.5 Eli Lilly and Company
                      6.5.1 Company Overview
                      6.5.2 Current Product Portfolio
                      6.5.3 Product Forecast Sales up to 2022
                      6.5.4 Strategic initiatives(Taltz)
                      6.5.5 Company - Key News Flow
                      6.5.6 Pipeline View
                      6.5.7 Pipeline Forecast
                      6.5.8 Catalysts and Event Calendar
                      6.5.9 SWOT Analysis
                  6.6 AstraZeneca
                      6.6.1 Company overview
                      6.6.2 Current Product Portfolio
                      6.6.3 Product Forecast Sales up to 2022
                      6.6.4 Strategic Initiatives(Siliq)
                      6.6.5 Company - Key News Flow
                      6.6.6 SWOT Analysis
                  6.7 Celgene Corporation
                      6.7.1 Company Overview
                      6.7.2 Current Product Portfolio
                      6.7.3 Product Forecast Sales up to 2022
                      6.7.4 Strategic Initiatives(Otezla)
                      6.7.5 Company - Key News Flow
                      6.7.6 Pipeline View
                      6.7.7 Pipeline Forecast
                      6.7.8 Catalysts and Event Calendar
                      6.7.9 SWOT Analysis
                  6.8 UCB
                      6.8.1 Company Overview
                      6.8.2 Current Product Portfolio
                      6.8.3 Product Forecast Sales up to 2022
                      6.8.4 Strategic Initiatives(Cimzia)
                      6.8.5 Company - Key News Flow
                      6.8.6 Pipeline View
                      6.8.7 Pipeline Forecast
                      6.8.8 Catalysts and Event Calendar
                      6.8.9 SWOT Analysis
                  6.9 Merck
                      6.9.1 Company Overview
                      6.9.2 Current Product Portfolio
                      6.9.3 Product Forecast Sales up to 2022
                      6.9.4 Strategic Initiatives(Ilumya)
                      6.9.5 Company - Key News Flow
                      6.9.6 Pipeline View
                      6.9.7 Pipeline Forecast
                      6.9.8 Catalysts and Event Calendar
                      6.9.9 SWOT Analysis

Chapter 7 Market Outlook
                  7.1 What the Future Holds
                  7.2 Winners and Losers
                  7.3 Emerging Companies
                  7.4 The Road Ahead

List of Tables

TABLE 1 Current Prevalence Across Seven Major Markets - 2016
TABLE 2 Current Incidence Across Seven Major Markets - 2016
TABLE 3 Forecast Global Prevalence 2016 - 2022
TABLE 4 Forecast Global Incidence 2016 - 2022
TABLE 5 Forecast Prevalence for Seven Major Markets 2016 - 2022
TABLE 6 Forecast Incidence for Seven Major Markets 2016 - 2022
TABLE 7 Psoriasis drugs market Size and Forecast (in $million)
TABLE 8 Geographic Sales Performance (in $million)
TABLE 9 Psoriasis drugs market, by Drug Class (in $million)
TABLE 10 Psoriasis Drugs Market Share, by Company (in $million)
TABLE 11 Patent Expiry Schedule
TABLE 12 Psoriasis Deals Landscape
TABLE 13 Psoriasis Drugs under Development
TABLE 14 Psoriasis - Late-Stage Pipeline
TABLE 15 Global Psoriasis Pipeline Forecast
TABLE 16 Product Profile: Risankizumab
TABLE 17 Product Profile: Bimekizumab
TABLE 18 Product Portfolio: Humira
TABLE 19 Humira Forecast Sales up to 2022
TABLE 20 AbbVie Pipeline View
TABLE 21 AbbVie Catalysts and Event Calendar
TABLE 22 Product Portfolio: Enbrel
TABLE 23 Enbrel Forecast Sales up to 2022
TABLE 24 Amgen Pipeline View
TABLE 25 Amgen Catalysts and Event Calendar
TABLE 26 Product Portfolio: Remicade
TABLE 27 Product Portfolio: Stelara
TABLE 28 Product Portfolio: Tremfya
TABLE 29 Remicade Forecast Sales up to 2022
TABLE 30 Stelara Forecast Sales up to 2022
TABLE 31 Tremfya Forecast Sales up to 2022
TABLE 32 Johnson & Johnson Pipeline View
TABLE 33 Johnson & Johnson Catalysts and Event Calendar
TABLE 34 Product Portfolio: Cosentyx
TABLE 35 Cosentyx Forecast Sales up to 2022
TABLE 36 Novartis Pipeline View
TABLE 37 Novartis Catalysts and Event Calendar
TABLE 38 Product Portfolio: Taltz
TABLE 39 Taltz Forecast Sales up to 2022
TABLE 40 Eli Lilly Pipeline View
TABLE 41 Eli Lilly Catalysts and Event Calendar
TABLE 42 Product Portfolio: Siliq
TABLE 43 Siliq Forecast Sales up to 2022
TABLE 44 Product Portfolio: Otezla
TABLE 45 Otezla Forecast Sales up to 2022
TABLE 46 Celgene Pipeline View
TABLE 47 Celgene Catalysts and Event Calenadar
TABLE 48 Product Portfolio: Cimzia
TABLE 49 Cimzia Forecast Sales up to 2022
TABLE 50 UCB Pipeline View
TABLE 51 UCB Catalysts and Event Calenadar
TABLE 52 Product Portfolio: Ilumya
TABLE 53 Ilumya Forecast Sales up to 2022
TABLE 54 Merck Pipeline View
TABLE 55 Merck Catalysts and Event Calenadar

List of Figures

FIG. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain Based Sizing & Forecasting
FIG. 6 QFD Modelling for Market Share Assessment
FIG. 7 Current Prevalence Across Seven Major Markets - 2016
FIG. 8 Current Incidence Across Seven Major Markets - 2016
FIG. 9 Global Psoriasis Epidemiology 2016 - 2022
FIG. 10 Market segmentation & scope
FIG. 11 Psoriasis drugs market, by Country :Forecast 2016 - 2022
FIG. 12 Psoriasis drugs market, by Therapeutic class: Forecast 2016 - 2022
FIG. 13 Psoriasis drugs market, by Treatment :Forecast 2016 - 2022 (in $million)
FIG. 14 Psoriasis Market, by Treatment :Topical Forecast 2016 - 2022 (in million)
FIG. 15 Psoriasis Market, by Treatment :Systemic Forecast 2016 - 2022 (in million)
FIG. 16 Psoriasis Market, by Treatment : Biologics Forecast 2016 - 2022 (in million)
FIG. 17 U.S. Psoriasis Market, by Treatment : Forecast 2016 - 2022 (in $million)
FIG. 18 U.S. Psoriasis Market, by Therapeutic class : Forecast 2016 - 2022 (in $million)
FIG. 19 EU5 Psoriasis Market, by Treatment : Forecast 2016 - 2022 (in $million)
FIG. 20 EU5 Psoriasis Market, by Therapeutic class : Forecast 2016 - 2022 (in $million)
FIG. 21 Japan Psoriasis Market, by Treatment : Forecast 2016 - 2022 (in $million)
FIG. 22 Japan Psoriasis Market, by Therapeutic class : Forecast 2016 - 2022 (in $million)
FIG. 23 Psoriasis Market Share, by Company 2016A-2022E
FIG. 24 Market Trends & Outlook
FIG. 25 Market Driver Relevance Analysis (Current & future impact)
FIG. 26 Market Restraint Relevance Analysis (Current & future impact)
FIG. 27 SWOT Analysis (Psoriasis Therapeutic Sector)
FIG. 28 Psoriasis Pipeline Assets
FIG. 29 SWOT Analysis (AbbVie)
FIG. 30 SWOT Analysis (Amgen)
FIG. 31 SWOT Analysis (Johnson & Johnson)
FIG. 32 SWOT Analysis (Novartis)
FIG. 33 SWOT Analysis (Eli Lilly)
FIG. 34 SWOT Analysis (AstraZeneca)
FIG. 35 SWOT Analysis (Celgene)
FIG. 36 SWOT Analysis (UCB)
FIG. 37 SWOT Analysis (Merck)